



GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Caerdydd a'r Fro  
Cardiff and Vale  
University Health Board

**Freedom of Information Act 2000 - Request Reference FoI/22/130**

**Immunoglobulin Treatments**

**Information Requested:**

**1. In the past 6 months (latest 6 months available) how many patients have received the following Immunoglobulin treatments (for any disease):**

- Cutaquig
- Cuvitru
- Gammanorm
- Hizentra
- Hyqvia
- Subgam
- Privigen
- Octagam
- Intratect
- Gamunex
- Kiovig
- Panzyga
- Iqymune
- Gammalex

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees' regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.





GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Caerdydd a'r Fro  
Cardiff and Vale  
University Health Board

**2. In the past 6 months (latest 6 months available) how many patients have received the following treatments (for any disease):**

- Berinert (Human C1-esterase inhibitor) – 0
- Cinryze (Human C1-esterase inhibitor) – 0
- Firazyr (Icatibant injection) – 27
- Orladeyo (Berotralstat) – 2
- Ruconest (Recombinant Human C1-esterase inhibitor) – 1
- Takhzyro (Lanadelumab) – 3

**3. In the past 2 years, how many patients have been diagnosed (primary and secondary) with Hereditary Angioedema (ICD-10 code D84.1)**

3\*

\*Please note that these are patients coded with Hereditary Angioedema and may not be new diagnoses of the condition.

**4. For the patients identified in Q3 above, how many patients have been treated (for any condition) in the past 6 months with the following drugs:**

- Danazol
- Oxandralone
- Stanozolol

Please see the response to question 1.

